Furthermore, the recent development of potent highly selective BRAF and MEK inhibitors with unique pharmacologic profiles, has led to the potential for improved survival of patients with locally advanced or metastatic melanoma. This evidence concerns the gene MAP2K7 and metastatic melanoma.